Skip to main content

Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

Active, not recruiting · Phase 1, Phase 2 · NCT04127578

Conditions: Parkinson Disease

At a glance

Research payments reported, 2025
$1.2M
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
32

About the trial

Sponsor
Prevail Therapeutics (with Eli Lilly and Company)
Tested
LY3884961 (biological), Methylprednisolone (drug), Sirolimus (drug)
Dates
Started 2020-01-03; completion 2031-08-31
Results posted
Not yet

Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at least 1 pathogenic GBA1 mutation. Two dose level cohorts of LY3884961 are planned (Dose Level 1 and Dose Level 2). The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and clinical efficacy measures. Patients will continue to be followed for an additional 4 years to continue to monitor safety as well as selected biomarker and efficacy measures.

From ClinicalTrials.gov, last updated 2026-10-13. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.2M in research payments for this study in 2025 (6 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.